Abstract

Monte Carlo Analysis of Different Administration Regiments for Isavuconazole against <i>Candida spp.</i> and <i>Aspergillus spp.</i>

Highlights

  • At present, invasive fungal infection is one of the major infectious diseases in the world, and its main pathogenic bacterias are Aspergillus and Mucor, which is the main cause of high morbidity and mortality, and is one of the most serious disease burdens in the world [1]

  • Isavuconazole is a triazole antifungal drug that inhibits the conversion of lanosterol to ergosterol by inhibiting cytochrome P450 (CYP)-dependent 14-α-demethylase in fungal cell membranes, thereby affecting the growth and replication of fungal cells

  • Isavuconazole is broad, and in vitro activity tests have confirmed that Isavuconazole has inhibitory effects on mold, yeast, and dimorphic fungi [4] [5] [6], which was currently approved by the FDA for the treatment of primary treatment of invasive aspergillosis (IA) and mucormycosis, available in oral and intravenous forms [7]

Read more

Summary

Introduction

Invasive fungal infection is one of the major infectious diseases in the world, and its main pathogenic bacterias are Aspergillus and Mucor, which is the main cause of high morbidity and mortality, and is one of the most serious disease burdens in the world [1]. Due to the safety and effectiveness of therapeutic drugs and other reasons, the treatment is less selective [2]. Isavuconazole is a triazole antifungal drug that inhibits the conversion of lanosterol to ergosterol by inhibiting cytochrome P450 (CYP)-dependent 14-α-demethylase in fungal cell membranes, thereby affecting the growth and replication of fungal cells. Isavuconazole is broad, and in vitro activity tests have confirmed that Isavuconazole has inhibitory effects on mold, yeast, and dimorphic fungi [4] [5] [6], which was currently approved by the FDA for the treatment of primary treatment of invasive aspergillosis (IA) and mucormycosis, available in oral and intravenous forms [7]. In this study, combined with antifungal pharmacokinetics (PK)/pharmacodynamics (PD) and microbial information, Monte Carlo simulation was used to analyze the treatment regiments for Isavuconazole against

Objectives
Methods
Results
Conclusion

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.